- Home
- ZBAI vs QNRX Comparison
ZBAI vs QNRX Comparison
Compare ZBAI & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZBAI | QNRX |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 10.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ZBAI | QNRX |
|---|---|---|
| Price | $7.06 | $9.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.2K | ★ 32.7K |
| Earning Date | 03-12-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 93.55 | N/A |
| 52 Week Low | $4.83 | $5.01 |
| 52 Week High | $44.64 | $41.80 |
Technical Indicators
Market Signals| Indicator | ZBAI | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 34.01 |
| Support Level | $6.88 | $9.59 |
| Resistance Level | $7.21 | $11.88 |
| Average True Range (ATR) | 0.34 | 0.84 |
| MACD | 0.06 | -0.28 |
| Stochastic Oscillator | 86.18 | 2.95 |
Price Performance
Historical ComparisonAbout ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial consulting services to small and medium-sized enterprises. It operates in one operating segment, which is the consulting service business. The company prominently generated revenues from consulting services to its clients. Geographically, the maximum revenue is derived from Hong Kong.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.